← All companies ← TTWO Manual TW → ← TRLV Pharmaceuticals UPB →
TVTX, Travere Therapeutics
We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases.
Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (" FSGS").
Our research and development efforts are at the forefront of our mission to address the unmet needs of patients and we support this innovation by reinvesting revenues from our commercialized products.
The business
What it sells, where the money comes from, the kind of company it is.
Next report By 8/9 · the 10-Q for the quarter ended late June · due within 40 days of period end · has filed ~32 days after · the wire records it on arrival
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- What it is
- Revenue is FILSPARI (66%), Tiopronin products (18%) and License (16%).
- Situation
- Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Operating margin has run around −84% through the cycle on a 97% gross margin, the operating line in the red even at its best — so the lever is whether the spending below the gross line can come down enough to clear a profit: revenue growth against the cost curve, and the cash runway until it does. Stock-based pay runs about 16% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −35%, above 15% in 0 of 10 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 10-K →FILSPARI is 66% of revenue, with Tiopronin products the other meaningful line at 18%.
- FILSPARI66%$322M
- Tiopronin products18%$88M
- License16%$80M
From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMMar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $134M | $155M | $164M | $175M | $198M | $132M | $109M | $145M | $233M | $491M | $536M | RevenueRevenue |
| $129M | $151M | $159M | $170M | $192M | $128M | $105M | $134M | — | $480M | $529M | Gross profitGross prof. |
| 97% | 98% | 97% | 97% | 97% | 97% | 96% | 92% | — | 98% | 99% | Gross marginGross mgn |
| 69% | 65% | 63% | 74% | 68% | 96% | 180% | 183% | 113% | 69% | 67% | SG&A / revenueSG&A/rev |
| 53% | 50% | 75% | 80% | 66% | 153% | 7% | 169% | 93% | 42% | 40% | R&D / revenueR&D/rev |
| ($58M) | ($54M) | ($80M) | ($137M) | ($176M) | ($199M) | ($320M) | ($388M) | ($324M) | ($63M) | ($57M) | Operating incomeOp. inc. |
| −43.6% | −34.7% | −48.7% | −78.3% | −88.8% | −151.3% | −292.2% | −267.2% | −138.9% | −12.8% | −10.6% | Operating marginOp. mgn |
| ($58M) | ($58M) | ($102M) | ($146M) | ($189M) | ($217M) | ($331M) | ($376M) | ($321M) | ($49M) | — | Pretax incomePretax |
| ($48M) | ($60M) | ($103M) | ($146M) | ($169M) | ($180M) | ($278M) | ($111M) | ($322M) | ($26M) | ($21M) | Net incomeNet inc. |
| Cash flow & returns | |||||||||||
| ($3M) | $7M | ($25M) | ($58M) | ($43M) | ($15M) | ($186M) | ($280M) | ($237M) | $38M | $40M | Operating cash flowOp. cash |
| $16M | $18M | $19M | $20M | $25M | $13M | $21M | $39M | $44M | $61M | $73M | DepreciationDeprec. |
| ($775K) | $22M | $39M | $47M | $78M | $123M | $33M | ($251M) | $4M | ($42M) | ($62M) | Working capital & otherWC & other |
| $1M | $887K | $727K | $195K | $7M | $5M | $191K | $668K | — | — | $668K | CapexCapex |
| 1.1% | 0.6% | 0.4% | 0.1% | 3.4% | 3.9% | 0.2% | 0.5% | — | — | 0.1% | Capex / revenueCapex/rev |
| ($5M) | $7M | ($26M) | ($58M) | ($50M) | ($20M) | ($186M) | ($281M) | — | — | $39M | Owner earningsOwner earn. |
| −3.6% | 4.2% | −15.6% | −33.3% | −25.0% | −15.1% | −170.4% | −193.3% | — | — | 7.3% | Owner earnings marginOE mgn |
| ($5M) | $7M | ($26M) | ($58M) | ($50M) | ($20M) | ($186M) | ($281M) | — | — | $39M | Free cash flowFCF |
| −3.6% | 4.2% | −15.6% | −33.3% | −25.0% | −15.1% | −170.4% | −193.3% | — | — | 7.3% | Free cash flow marginFCF mgn |
| $615K | $0 | $0 | $0 | $95M | $0 | $0 | — | — | — | $0 | AcquisitionsAcquis. |
| $10M | $46M | ($203M) | $20M | ($61M) | ($138M) | ($33M) | $56M | $99M | $28M | — | Investing cash flowInv. cash |
| ($4M) | $5M | $232M | ($2M) | $128M | $232M | $118M | $219M | $139M | ($33M) | — | Financing cash flowFin. cash |
| $117K | ($58K) | ($135K) | ($9K) | ($1M) | $2M | ($3M) | $2M | ($913K) | $2M | — | Exchange-rate effectFX |
| $3M | $58M | $3M | ($40M) | $22M | $81M | ($104M) | ($4M) | $359K | $35M | — | Change in cashΔ cash |
| -15% | -18% | -15% | -30% | -41% | -43% | -71% | -59% | -82% | -15% | -14% | ROICROIC |
| -16% | -20% | -32% | -66% | -80% | -60% | -650% | -55% | -544% | -22% | -22% | Return on equityROE |
| −16% | −20% | −32% | −66% | −80% | −60% | −650% | −55% | −544% | −22% | −22% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $256M | $301M | $103M | $62M | $85M | $166M | $62M | $58M | $59M | $93M | $245M | Cash & investmentsCash+inv |
| $19M | $14M | $13M | $18M | $16M | $16M | $17M | $21M | $27M | $80M | $87M | ReceivablesReceiv. |
| $3M | $5M | $6M | $6M | $8M | $7M | $5M | $9M | $42M | $36M | $37M | InventoryInvent. |
| $8M | $19M | $7M | $27M | $12M | $15M | $17M | $42M | $24M | $25M | $13M | Accounts payablePayables |
| $14M | $285K | $11M | ($2M) | $11M | $8M | $4M | ($11M) | $45M | $91M | $111M | Operating working capitalOper. WC |
| $332M | $326M | $496M | $429M | $410M | $583M | $486M | $617M | $417M | $438M | $393M | Current assetsCur. assets |
| $83M | $86M | $105M | $95M | $93M | $124M | $142M | $178M | $201M | $160M | $125M | Current liabilitiesCur. liab. |
| 4.0× | 3.8× | 4.7× | 4.5× | 4.4× | 4.7× | 3.4× | 3.5× | 2.1× | 2.7× | 3.1× | Current ratioCurr. ratio |
| $3M | $3M | $3M | $3M | $9M | $11M | $9M | $7M | $5M | $4M | — | Net PP&ENet PP&E |
| $936K | $936K | $936K | $936K | $900K | $900K | $800K | $800K | $800K | — | $800K | GoodwillGoodwill |
| $525M | $520M | $709M | $605M | $607M | $777M | $673M | $789M | $594M | $605M | $555M | Total assetsAssets |
| $44M | $45M | $195M | $205M | $215M | $227M | $376M | $377M | $310M | $312M | $312M | Total debtDebt |
| ($211M) | ($256M) | $92M | $142M | $131M | $61M | $314M | $319M | $252M | $219M | $67M | Net debt / (cash)Net debt |
| -12.3× | -12.2× | -8.2× | -7.3× | -9.2× | -10.1× | -29.1× | -34.3× | -29.0× | -5.8× | -5.6× | Interest coverageInt. cov. |
| $218M | $227M | $391M | $384M | $396M | $475M | $630M | $588M | $535M | $490M | — | Total liabilitiesTotal liab. |
| $308M | $293M | $318M | $221M | $211M | $302M | $43M | $201M | $59M | $115M | $99M | Shareholders’ equityEquity |
| 21.8% | 17.3% | 12.0% | 12.0% | 11.9% | 22.4% | 34.8% | 30.5% | 15.8% | 9.1% | 9.2% | Stock comp / revenueSBC/rev |
| Per share | |||||||||||
| 38.3M | 38.8M | 40.4M | 42.3M | 47.5M | 59.8M | 63.8M | 74.3M | 78.9M | 89.2M | 91.9M | Shares out (diluted)Shares |
| $3.49 | $4.00 | $4.06 | $4.14 | $4.17 | $2.20 | $1.72 | $1.96 | $2.96 | $5.50 | $5.84 | Revenue / shareRev/sh |
| $-1.25 | $-1.54 | $-2.54 | $-3.46 | $-3.56 | $-3.01 | $-4.37 | $-1.50 | $-4.08 | $-0.29 | $-0.23 | EPS (diluted)EPS |
| $-0.13 | $0.17 | $-0.64 | $-1.38 | $-1.04 | $-0.33 | $-2.92 | $-3.78 | — | — | $0.42 | Owner earnings / shareOE/sh |
| $-0.13 | $0.17 | $-0.64 | $-1.38 | $-1.04 | $-0.33 | $-2.92 | $-3.78 | — | — | $0.42 | Free cash flow / shareFCF/sh |
| $0.04 | $0.02 | $0.02 | $0.00 | $0.14 | $0.09 | $0.00 | $0.01 | — | — | $0.01 | Cap. spending / shareCapex/sh |
| $8.04 | $7.56 | $7.87 | $5.22 | $4.44 | $5.05 | $0.67 | $2.70 | $0.75 | $1.29 | $1.07 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +5.2%/yr | +5.7%/yr |
| Capital spending / share | −18.4%/yr (7-yr) | −12.9%/yr |
| Book value / share | −18.4%/yr | −21.9%/yr |
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2023 the business reported a $111M loss but ($281M) of owner earnings: $169M less than the profit line, taken out by capital spending and the timing of cash.
| FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|
| Reported net income | ($111M) | ($278M) | ($180M) | ($169M) | ($146M) |
| Depreciation & amortizationnon-cash charge added back | +$39M | +$21M | +$13M | +$25M | +$20M |
| Stock-based compensationreal costnon-cash, but a real cost | +$44M | +$38M | +$30M | +$24M | +$21M |
| Working capital & othertiming of cash in and out, other non-cash items | −$251M | +$33M | +$123M | +$78M | +$47M |
| Cash from operations | ($280M) | ($186M) | ($15M) | ($43M) | ($58M) |
| Capital expenditurecash put back in to keep running and to grow | −$668K | −$191K | −$5M | −$7M | −$195K |
| Owner earnings | ($281M) | ($186M) | ($20M) | ($50M) | ($58M) |
| Owner-earnings marginowner earnings ÷ revenue | -193% | -170% | -15% | -25% | -33% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $44M), owner earnings is nearer ($325M).
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? -5.8×Does not cover its interestOperating income ($63M) ÷ interest expense $11M
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net debt against an operating lossCash $93M − debt $312M
What this means
Netting $93M of cash and short-term investments against $312M of debt leaves $219M owed, with no operating profit this year to measure it against — understand that combination before anything else about the company. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 60 + DIO 1276 − DPO 876 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle10-yr median, range -82%–-15%; -15% latest = NOPAT ($50M) ÷ invested capital $334MIndustry peers: median -6%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran -15% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Not enough dataIndustry peers: median -16%
What this means
The filing data didn't include the inputs for this check.
- Loss, but cash-generativeNet income ($26M) · cash from operations $38M
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? —Not enough data
What this means
The filing data didn't include the inputs for this check.
The promise and the pay packet
- Is the buyback buying ownership, or mopping up? 9.1%The count is risingStock compensation $45M (fiscal 2025), 9.1% of revenue · no repurchases · diluted shares +39.9% since 2022
What this means
Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.
Graham’s defensive tests · 1 of 4 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $491M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 2.74×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt NearDebt ≤ working capital · $312M vs $278M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 10 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record —Uninterrupted dividends · no dividend line tagged in the data
What this means
An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-1.64/share (latest year $-0.27), the averaged base the calculator's gate runs on, and book value is $1.23/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 0 of 10
What this means
Lost money in 10 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 0 of 10 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin −42% → −140% (3-yr avg ends)
In the filing’s words The filing ties gains to its own pricing, but names price competition too — pricing power that is real yet contested, not unopposed. The margin shows who is winning.
What this means
The recent-years average (−140%) sits below the early years (−42%), but the latest year (−13%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is −89% — read it across the cycle, not on the dip.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Worst year 2022 · −292.2% op. margin
What this means
Operations went underwater in 2022, understand why before trusting the good years.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Mar 31, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$245M
- Receivables$87M
- Inventory$37M
- Other current assets$24M
- Accounts payable$13M
- Other current liabilities$113M
From the company's latest filing.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.
| Fiscal year | Chief executive | Pay, as filed | “Actually paid” | Owner earnings |
|---|---|---|---|---|
| 2021 | (1) | $5.7M | $6.6M | ($20M) |
| 2022 | (1) | $5.8M | $687k | ($186M) |
| 2023 | (1) | $7.6M | $885k | ($281M) |
| 2024 | (1) | $5.2M | $10.9M | — |
| 2025 | (1) | $8.5M | $24.5M | — |
Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.
- Insider ownership4.4%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- CEO pay ratio23:1
What the chief earns for every dollar the median employee makes, per the 2026 proxy. A high ratio alone settles nothing; some businesses are genuinely top-heavy in scarce skill. A runaway figure is where Buffett starts asking whether the board is doing its job.
- Stock-based compensation$45M
The slice of the business handed to employees in shares in fiscal 2025, 9.1% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
What an owner would ask, FY2025
read the 10-K →- Which reported numbers are a judgment call?Management names Revenue recognition, Stock compensation as critical estimates
each rests partly on management's judgment; the filing's note sets out the assumptionsverify →
The questions the record and the charts do not answer on their own; each carries the figure and the place to look.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| CPRXCatalyst Pharmaceuticals Inc. | $589M | 86% | 37.2% | 48% | 38% |
| HCMHUTCHMED (China) Limited | $549M | 35% | -32.7% | -23% | -16% |
| MIRMMirum Pharmaceuticals Inc. | $521M | — | -42.3% | -61% | -18% |
| BBIOBridgeBio Pharma Inc. | $502M | 96% | -656.4% | -154%1y | -546% |
| TVTXTravere Therapeutics | $491M | 97% | -83.6% | -35% | -20% |
| NATRNature's Sunshine Products Inc. | $480M | 73% | 4.3% | 12% | 4% |
| ZLABZai Lab Limited | $457M | 65% | -163.8% | -103% | -127% |
| INVAInnoviva Inc. | $411M | 79%3y | 85.6% | 44% | 63% |
| Group median | — | 79% | -37.5% | -29% | -17% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Travere Therapeutics has delivered.
—
9.0% = the 4.68% 10-year Treasury (Jul 30, 2026) + 4.32 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.68%, as of Jul 30, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings $39M on 93M shares outstanding, per the 10-Q cover, as of 2026-04-30; net debt $67M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← TTWO its page in the Manual TW →
Industry order: ← TRLV the Pharmaceuticals chapter UPB →